Partnership leverages real-world patient insights and AI to improve screening and advance health equity in communities most impacted by prostate cancer
Komodo Health, a leader in AI-powered healthcare intelligence, has announced a strategic partnership with ZERO Prostate Cancer, one of the nation’s leading prostate cancer advocacy and patient support organizations. The collaboration aims to strengthen efforts to close screening gaps and improve care access through ZERO’s national initiative, “Blitz the Barriers,” which focuses on reducing disparities in prostate cancer diagnosis and treatment.
Prostate cancer remains one of the most significant health challenges facing men in the United States. It is currently the second-leading cause of cancer-related deaths among American men. In 2026 alone, approximately 333,830 new cases and 36,320 deaths are expected nationwide. After years of decline, recent data shows that prostate cancer incidence is increasing again as screening patterns shift, while the long-term decline in mortality rates has slowed. These trends highlight the urgent need for improved screening programs, earlier diagnosis, and more equitable access to treatment.
Health Technology Insights: https://healthtechnologyinsights.com/how-healthtech-is-rethinking-early-detection-with-smart-screening/
The Blitz the Barriers initiative was created to eliminate racial and socioeconomic disparities in prostate cancer care. The program focuses on expanding access to screening, patient navigation services, and culturally tailored education for communities that face the greatest barriers to healthcare. Key populations include Black men, military veterans, and individuals living in underserved rural areas where healthcare resources are limited.
Courtney Bugler, Chief Executive Officer of ZERO Prostate Cancer, emphasized the importance of data-driven decision-making in addressing these challenges. She noted that prostate cancer outcomes are often shaped by geographic access to healthcare, availability of screening programs, and the speed at which patients receive follow-up care. Through the partnership with Komodo Health, ZERO will gain the ability to identify screening gaps and underserved patient populations more quickly, allowing the organization to allocate resources where they can have the greatest impact.
Komodo Health’s AI-powered healthcare platform will provide insights into patient journeys using its Healthcare Map®, a comprehensive dataset that captures de-identified healthcare interactions across more than 330 million patients. By analyzing real-world patient data, the platform enables healthcare organizations to detect gaps in screening programs, identify delays in care pathways, and better understand disparities in prostate cancer treatment outcomes.
Miles Ennis, Chief Operating Officer of Komodo Health, highlighted the role of AI in advancing healthcare equity. He explained that patient advocacy organizations require sophisticated analytics tools to operate effectively in highly regulated healthcare environments. By combining AI-driven insights with oncology expertise, the partnership aims to translate healthcare data into practical action that supports earlier diagnosis and more equitable care delivery.
The Blitz the Barriers program launched its first pilot in Atlanta in 2025 and is now expanding to additional cities with significant prostate cancer disparities, including Baltimore, Washington, D.C., New Orleans, Detroit, and Houston. With support from partners such as Novartis, the initiative aims to expand screening access and ultimately save 100,000 lives by 2035.
By combining advanced healthcare analytics with community-based outreach programs, the partnership between Komodo Health and ZERO Prostate Cancer demonstrates how AI in healthcare can help address disparities, improve early detection, and strengthen patient outcomes across vulnerable communities.
Health Technology Insights: https://healthtechnologyinsights.com/health-technology-innovations-can-boost-healthspan-worldwide/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
